好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Characterizing a Population Reporting Menstrually Related Migraine: Multi-country Results from the Chronic Migraine Epidemiology and Outcomes–international (CaMEO-I) Study
Headache
P8 - Poster Session 8 (11:45 AM-12:45 PM)
15-002

To characterize a population reporting menstrual migraine (MM) in CaMEO-I study respondents from the United States (US), Canada, France, Germany, the United Kingdom (UK), and Japan.

MM is defined as migraine attacks occurring in the perimenstrual window. MM attacks can be longer-lasting, more severe, and less responsive to treatment compared with non-menstrual migraine attacks.
CaMEO-I was a cross-sectional, web-based survey conducted in 2021-2022. Among all CaMEO-I respondents from multiple countries, this analysis included adult females (age: 18 to 50 years) meeting International Classification of Headache Disorders, 3rd edition (ICHD-3) migraine criteria; those who were postmenopausal or pregnant were excluded. Participants self-reported migraine or “severe headaches” occurring around the onset of menstruation. Acute treatment optimization was evaluated with the 4-item Migraine Treatment Optimization Questionnaire (mTOQ-4). The sum of the items was used to categorize treatment optimization as very poor (0), poor (1–5), moderate (6–7), or maximum (8). Group differences in treatment optimization were examined across the mTOQ categories using chi-square tests.

Of 14,492 CaMEO-I respondents, 6,395 (44.1%) met eligibility criteria. Of these, 5.1% (327/6395) reported all migraine attacks, and 61.0% (3901/6395) reported at least some attacks around menstruation. Among eligible respondents, the mean (SD) age was 33.4 (8.8) years, 7.2% (462/6395) had chronic migraine, and 21.9% (1402/6395) were obese. Menstrually related headaches/migraine diagnosis was reported in 14.8% (947/6395) of respondents, either by self-report or clinician diagnosis. Across countries, the majority of women had poor treatment optimization [mTOQ very poor: 8.1% (474/5832), poor: 53.8% (3139/5832), moderate: 22.3% (1299/5832), and maximum: 15.8% (920/5832); P<.001].

Across multiple countries, MM was common and associated with poor acute treatment optimization, underscoring a substantial unmet need in effective management. These findings highlight opportunities to improve care strategies for women affected by MM worldwide.
Authors/Disclosures
Jessica Ailani, MD, FAAN (Medstar Georgetown Neurology)
PRESENTER 		Dr. Ailani has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Abbvie. Dr. Ailani has received personal compensation in the range of $0-$499 for serving as a Consultant for Eli Lilly. Dr. Ailani has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lundbeck. Dr. Ailani has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ipsen. Dr. Ailani has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Merz. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Aspya. Dr. Ailani has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Axsome. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bausch. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amneal. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Satsuma. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Kallyope. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Self Magazine. The institution of Dr. Ailani has received research support from Ipsen. The institution of Dr. Ailani has received research support from Parema. The institution of Dr. Ailani has received research support from Lundbeck. The institution of Dr. Ailani has received research support from Merz. The institution of Dr. Ailani has received research support from Pfizer. Dr. Ailani has received research support from Mi-Helper. The institution of Dr. Ailani has received research support from ShiraTronic. Dr. Ailani has a non-compensated relationship as a Executive Board Member with American Headache Society that is relevant to AAN interests or activities.
Jelena M. Pavlovic, MD, PhD (Albert Einstein College of Medicine) Dr. Pavlovic has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biohaven.
Deena Kuruvilla, MD (Westport Headache Institute) Dr. Kuruvilla has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer. Dr. Kuruvilla has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Abbvie. Dr. Kuruvilla has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Abbvie/Allergan. Dr. Kuruvilla has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for HPMB.
Nicole Naccara (Abbvie) Dr. Naccara has received personal compensation for serving as an employee of Abbvie . Dr. Naccara has stock in Abbvie.
Kristina M. Fanning, PhD (MIST Reserach) The institution of Dr. Fanning has received research support from Abbvie. The institution of Dr. Fanning has received research support from NYC Langone Health . The institution of Dr. Fanning has received research support from Uiversity of SC - Irvine. The institution of Dr. Fanning has received research support from AESARA.
Janette Contreras-De Lama Janette Contreras-De Lama has received personal compensation for serving as an employee of AbbVie. Janette Contreras-De Lama has stock in AbbVie.
Dawn C. Buse, PhD (Dawn C. Buse, PhD) Dr. Buse has received personal compensation for serving as an employee of Vector Psychometric Group. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie-Allergan. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amgen. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lilly. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lundbeck. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Theranicsa. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lilly. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie-Allergan. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Buse has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Current Pain and Headache Reports. The institution of Dr. Buse has received research support from Amgen. The institution of Dr. Buse has received research support from FDA. The institution of Dr. Buse has received research support from National Headache Foundation.